Ariane Park, MD
Neurology · Gahanna, OHNPI 1093977431
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $981 of the $1,473 with a category attached, or 66.6%. UCB, Inc. accounts for 89.2% of it on its own, with 2 other manufacturers making up the rest. 2023 is the largest year on record at $1,314, 8.9 times the $148 reported in 2019.
Across 11 payments — averaging $133.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$1K
- Abiomed$148
- AbbVie$12
Across 35 payments — averaging $13,621 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$322K
- Sage Therapeutics, LLC$87K
- AbbVie$61K
- Sunovion Pharmaceuticals Inc.$7K
What the payments were for
- Travel & lodging$98167%
- Food & beverage$49333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$148
How this compares
$1,473 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 11 | $25,530 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 138 | $3,669 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 42 | $1,719 |
| AmantadineAmantadine Hcl | 16 | $976 |
| Primidone | 38 | $746 |
| Propranolol Hcl | 24 | $526 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 12 | $130 |
| Donepezil Hcl | 12 | $74 |
| Sertraline Hcl | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other neurology in Gahanna
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.